Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Richard R. Berges
Observed names:
R Berges,
R R Berges,
R. Berges,
R. R. Berges,
R.R. Berges,
RICHARD BERGES,
Richard Berges,
Richard R Berges
show all 8
Observed institutions:
University of Maryland, Baltimore,
Johns Hopkins University,
Johns Hopkins Medicine,
Medizinische Hochschule Hannover,
Universitätsklinik Marien Hospital Herne,
Johns Hopkins Hospital,
University Hospital Cologne,
Ruhr University Bochum
show all 8
OpenAlex ID:
A5111629845
Implication of cell kinetic changes during the progression of human prostatic cancer.
1995
·
R R Berges
, J Vukanovic
, et al.
·
PubMed
·
342
Randomised, placebo-controlled, double-blind clinical trial of β-sitosterol in patients with benign prostatic hyperplasia
1995
·
R.R. Berges
, J. Windeler
, et al.
·
The Lancet
·
289
Prospective, Randomized, Multinational Study of Prostatic Urethral Lift Versus Transurethral Resection of the Prostate: 12-month Results from the BPH6 Study
2015
·
Jens Sønksen
, Neil J. Barber
, et al.
·
European Urology
·
261
Prostatic urethral lift vs transurethral resection of the prostate: 2‐year results of the BPH 6 prospective, multicentre, randomized study
2016
·
Christian Gratzke
, Neil Barber
, et al.
·
British Journal of Urology
·
220
Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation.
1993
·
R R Berges
, Y Furuya
, et al.
·
Proceedings of the National Academy of Sciences
·
191
The Evolving Role of Oestrogens and Their Receptors in the Development and Progression of Prostate Cancer
2008
·
Helmut Bonkhoff
, Richard Berges
·
European Urology
·
189
Androgen Regulation of Programmed Death of Normal and Malignant Prostatic Cells
1992
·
JOHN T. ISAACS
, PER I. LUNDMO
, et al.
·
Journal of Andrology
·
168
PDF
Age-stratified normal values for prostate volume, PSA, maximum urinary flow rate, IPSS, and other LUTS/BPH indicators in the German male community-dwelling population aged 50 years or older
2011
·
Richard Berges
, Matthias Oelke
·
World Journal of Urology
·
116
The Efficacy of Drugs for the Treatment of LUTS/BPH, A Study in 6 European Countries
2006
·
Annie Hutchison
, Richard Farmer
, et al.
·
European Urology
·
116
Male Lower Urinary Tract Symptoms and Related Health Care Seeking in Germany
2001
·
Richard R. Berges
, L. Pientka
, et al.
·
European Urology
·
100
Medical Consumption and Costs during a One-Year Follow-up of Patients with LUTS Suggestive of BPH in Six European Countries: Report of the TRIUMPH Study
2005
·
N.J.A. van Exel
, M.A. Koopmanschap
, et al.
·
European Urology
·
82
Treatment of symptomatic benign prostatic hyperplasia with β‐sitosterol: an 18‐month follow‐up
2000
·
R.R. Berges
, A. Kassen
, et al.
·
British Journal of Urology
·
82
From pathogenesis to prevention of castration resistant prostate cancer
2009
·
Helmut Bonkhoff
, Richard Berges
·
The Prostate
·
79
Cell Kinetic in Epithelium and Stroma of Benign Prostatic Hyperplasia
1997
·
Siegfried Claus
, Richard Berges
, et al.
·
The Journal of Urology
·
71
Characteristics of Patients Presenting with LUTS/BPH in Six European Countries
2006
·
Annie Hutchison
, Richard Farmer
, et al.
·
European Urology
·
66
Current benign prostatic hyperplasia treatment: impact on sexual function and management of related sexual adverse events
2011
·
V. Mirone
, A. Sessa
, et al.
·
International Journal of Clinical Practice
·
58
PDF
Management of the BPH Syndrome in Germany: Who Is Treated and How?
1999
·
Richard R. Berges
, Ludger Pientka
·
European Urology
·
58
Minimally invasive prostatic urethral lift (PUL) efficacious in TURP candidates: a multicenter German evaluation after 2 years
2018
·
Karl-Dietrich Sievert
, Martin Schonthaler
, et al.
·
World Journal of Urology
·
55
PDF
Nocturia: state of the art and critical analysis of current assessment and treatment strategies
2014
·
Matthias Oelke
, Erika Adler
, et al.
·
World Journal of Urology
·
49
PDF
How Good do Current LHRH Agonists Control Testosterone? Can this be Improved with Eligard®?
2005
·
Bertrand Tombal
, Richard Berges
·
European Urology Supplements
·
41
Diagnostik und Differenzialdiagnostik des benignen Prostatasyndroms (BPS)
2009
·
R. Berges
, K. Dreikorn
, et al.
·
Der Urologe
·
39
Eligard®: Pharmacokinetics, Effect on Testosterone and PSA Levels and Tolerability
2005
·
Richard Berges
·
European Urology Supplements
·
38
Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer
2006
·
R. Berges
, U. Bello
·
Current Medical Research and Opinion
·
37
Nocturia and its impact on health-related quality of life and health care seeking behaviour in German community-dwelling men aged 50 years or older
2014
·
Matthias Oelke
, Birgitt Wiese
, et al.
·
World Journal of Urology
·
36
The Impact of Nocturia in Patients with LUTS/BPH: Need for New Recommendations
2005
·
Christopher R. Chapple
, Jose E. Batista
, et al.
·
European Urology Supplements
·
34
Show more works
View as search
Works count:
108
Citation count:
3,435
H-index:
30
I10-index:
48
Year
Topic
Type
